Rockefeller Capital Management
BIB icon

Rockefeller Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Rockefeller Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201 Buy
+2
New +$168 ﹤0.01% 4657

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Rockefeller Capital Management's BIB Position: Q2 2026 in Review

Rockefeller Capital Management opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2026: 2 shares worth $201. The stake represents ﹤0.01% of the portfolio and ranks #4657 among its holdings.

20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Rockefeller Capital Management held 2 shares of ProShares Ultra NASDAQ Biotechnology worth $201 as of Q2 2026.
  • ProShares Ultra NASDAQ Biotechnology was a new Rockefeller Capital Management position in Q2 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4657 holding.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.